Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Melanoma 4 Uveal Melanoma 1 Thyroid Cancer, Papillary 1 Testicular Neoplasms 1 Spondylitis, Ankylosing 1 Psoriasis 1 Lupus Erythematosus, Systemic 1 Inflammatory Bowel Diseases 1 Identification of Skin Cancer Biopsy Sites 1 Crohn Disease 1 Communication 1 Colitis, Ulcerative 1 Autoimmune Diseases 1 Arthritis, Rheumatoid 1 Arthritis, Reactive 1 Arthritis, Psoriatic 1 Adenocarcinoma, Follicular 1

Interventions

Ipilimumab 29 Nivolumab 23 pembrolizumab 14 incomplete Freund's adjuvant 10 Cyclophosphamide 10 Melphalan 9 Interleukin-2 9 CTLA-4 Antigen 8 tebentafusp 7 sargramostim 7 Temozolomide 7 MART-1 Antigen 7 Dacarbazine 7 Ranibizumab 6 montanide ISA 51 5 fludarabine phosphate 5 fludarabine 5 Sunitinib 5 Radiosurgery 5 Carboplatin 5 Blood Specimen Collection 5 Bevacizumab 5 aldesleukin 4 aflibercept 4 Surveys and Questionnaires 4 Magnetic Resonance Spectroscopy 4 Granulocyte-Macrophage Colony-Stimulating Factor 4 Biopsy 4 trametinib 3 sotrastaurin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Uveal Melanoma × Interviews as Topic × Dermatologic × Clear all

NCT06073548 2023-10-10

SALOME Quali

Institut Curie

Uveal Melanoma, Communication

Data powered by HemOnc (CC BY 4.0) Colophon ⚡